Progentec Diagnostics, Inc., was set up to explore and commercialize state of the art diagnostic interventions in therapeutic areas with a high level of unmet need. The company is collaborating with a number of research institutions and individuals around the world engaged in bringing the latest technological innovations to the field of diagnostics. The commitment to this cause is firmly rooted in our belief that better diagnostics would not only help in better and less costly management of diseases, but also help tremendously in reducing the incidence of diseases through early screening and detection.
Progentec's goal is to bring blood-based biomarkers and digital markers to inform innovative approaches to manage Lupus. Working towards this goal, Progentec has already developed a protein biomarker based platform with multiple diagnostic tests to manage Lupus at various stages of the disease. For this, the company has established strategic partnerships with the Oklahoma Medical Research Foundation and the Mayo Clinic. Progentec has also established a digital network of about 65,000 Lupus patients in the US through a patient portal and mobile app (LupusCorner), placing the company in a unique position to capture digital markers on an ongoing basis. Efforts have been initiated to further develop artificial intelligence driven algorithms to enhance the company's offerings.